logo-loader
HealthPharma & Biotech
viewCello Health PLC

Cello Group says tax man has widened scope of VAT probe

pound_coin350_54d8c81948175.jpg

The VAT oversight at one of its subsidiaries referred to in Cello's (LON:CLL) 22 January trading update may be bigger than first thought.

The company has received guidance from the tax man that the scope of the impending review may now include a wider range of items sold to charity clients of Cello subsidiary Cello Signal.

The detailed contracts and invoices have not yet been reviewed by the authorities, but the company conceded that the maximum potential liability could now in theory be in excess of the £1mln to £2mln range indicated at the time of the pre-close trading update, though it considers the possibility remote.

The marketing group said that Cello Signal had been acting in good faith in not charging VAT on certain items to charity clients and that it intends to robustly defend its historical position on the issue, which it believes has been in line with received historical industry-wide practice.

The board of Cello maintains that any backdated VAT assessment arising would be substantially contractually recoverable from clients should this be appropriate.

Cello's shares were down 3% at 88.25p in mid-afternoon trading.

Quick facts: Cello Health PLC

Price: 126 GBX

AIM:CLL
Market: AIM
Market Cap: £133.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cello Group hails the impact of a “vibrant” US on the company’s performance

Chief executive of Cello Group (LON:CLL) Mark Scott spoke to Proactive’s Charlotte Kan in the wake of an upbeat trading update from healthcare and strategic consumer marketing specialist. The research and communications operations both performed well, but there was a common theme to update...

on 05/11/2016

RNS

Holding(s) in Company

2 weeks ago

Total Voting Rights

2 weeks ago

Disposal

2 weeks, 5 days ago

Interim Results

on 09/18/2019

Holding(s) in Company

on 08/23/2019

Acquisition of ISS

on 08/16/2019

Total Voting Rights

on 08/06/2019

2 min read